Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Lowered to Hold at Zacks Investment Research

Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI “

Separately, HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 12th.

NYSEAMERICAN:ATNM traded down $0.35 during mid-day trading on Tuesday, hitting $5.57. 178,526 shares of the company’s stock traded hands, compared to its average volume of 593,434. Actinium Pharmaceuticals has a twelve month low of $4.41 and a twelve month high of $10.30.

Hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its holdings in shares of Actinium Pharmaceuticals by 21.8% in the third quarter. Rockefeller Capital Management L.P. now owns 8,381 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 1,500 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Actinium Pharmaceuticals by 132.9% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 8,833 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 5,040 shares in the last quarter. Virtu Financial LLC purchased a new position in Actinium Pharmaceuticals in the fourth quarter valued at $84,000. Dimensional Fund Advisors LP purchased a new position in Actinium Pharmaceuticals in the third quarter valued at $98,000. Finally, Wealthspire Advisors LLC purchased a new position in Actinium Pharmaceuticals in the third quarter valued at $127,000. Institutional investors own 8.63% of the company’s stock.

Actinium Pharmaceuticals Company Profile (Get Rating)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

See Also

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.